US Patent Issued to MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN IN DER, HELMHOLTZ-GEMEINSCHAFT; CHARITE-UNIVERSITATSMEDIZIN BERLIN on Sept. 23 for "CD22-specific T cell receptors and adoptive T cell therapy for treatment of B cell malignancies" (German Inventors)

ALEXANDRIA, Va., Sept. 23 -- United States Patent no. 12,421,290, issued on Sept. 23, was assigned to MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN IN DER (Berlin) and HELMHOLTZ-GEMEINSCHAFT; CHARITE-UNIVERSITATSMEDIZIN BERLIN (Berlin).

"CD22-specific T cell receptors and adoptive T cell therapy for treatment of B cell malignancies" was invented by Thomas Blankenstein (Berlin), Antonio Pezzutto (Berlin) and Simone Rhein (Berlin).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention is directed to the field of immunotherapy, in particular, adoptive T cell therapy or T cell receptor (TCR) gene therapy of cancer, in particular, of B cell lymphoma or B cell leukemia. The invention provides a nucleic ...